MBF-362 / Medibiofarma - LARVOL DELTA

First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Medibiofarma S.L. | Recruiting ➔ Completed | N=41 ➔ 16

Enrollment change • Trial completion • Oncology • Solid Tumor

First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors (clinicaltrials.gov) - P1 | N=41 | Recruiting | Sponsor: Medibiofarma S.L. | Trial primary completion date: Oct 2024 ➔ Jan 2025

Trial primary completion date • Oncology • Solid Tumor

First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors (clinicaltrials.gov) - P1 | N=41 | Recruiting | Sponsor: Medibiofarma S.L. | Trial primary completion date: May 2024 ➔ Oct 2024

Trial primary completion date • Oncology • Solid Tumor

First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors (clinicaltrials.gov) - P1 | N=41 | Recruiting | Sponsor: Medibiofarma S.L.

New P1 trial • Oncology • Solid Tumor